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Mutations in the gene encoding the microtubule (MT)-
severing protein spastin are the most common cause of
hereditary spastic paraplegia, a genetic condition in which
axonsofthe corticospinal tractsdegenerate.Weshowthat
not only does endogenous spastin colocalize with MTs,
but that it is also located on the early secretory pathway,
can be recruited to endosomes and is present in the
cytokinetic midbody. Spastin has two main isoforms,
a 68 kD full-length isoform and a 60 kD short form. These
two isoforms preferentially localize to different membrane
traffic pathways with 68 kD spastin being principally
located at the early secretory pathway, where it regulates
endoplasmic reticulum-to-Golgi traffic. Sixty kiloDalton
spastin is the major form recruited to endosomes and is
alsopresentinthemidbody,whereitslocalizationrequires
the endosomal sorting complex required for transport-III-
interacting MIT domain. Loss of midbody MTs accompa-
nies the abscission stage of cytokinesis. In cells lacking
spastin, a MT disruption event that normally accompanies
abscission does not occur and abscission fails. We suggest
that this event represents spastin-mediated MT severing.
Ourresultssupportamodelinwhichmembranetrafficand
MT regulation are coupled through spastin. This model is
relevant in the axon, where there also is co-ordinated MT
regulation and membrane traffic.
Key words: abscission, ER-to-Golgi traffic, ESCRT com-
plex, hereditary spastic paraplegia, spastin
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The hereditary spastic paraplegias (HSPs) are a group of
genetic neurodegenenerative disorders affecting the neu-
rons of the corticospinal tract. Neuropathologically, HSPs
show a length-dependent distal degeneration of the axons
of these neurons, causing progressive spastic paralysis
affecting the legs (1,2). The HSPs are therefore important
models for understanding molecular mechanisms involved
in axonal maintenance and degeneration.
Mutations in the spastin gene are the most frequent
cause of HSP, occurring in approximately 40% of auto-
somal dominant HSP families (3,4). The mutational
spectrum is broad and includes large deletions (some-
times encompassing the entire coding region), suggest-
ing that in many cases the pathological mechanism is
haploinsufficiency (5). Missense mutations in the aden-
osine triphosphatase (ATPase) domain are also common,
and these may act through haploinsufficiency or,
because spastin forms hexamers, by a dominant-nega-
tive effect (6,7).
There are two main spastin isoforms, coded from differing
translational initiation sites (Figure 1). Translation begin-
ning at the first ATG results in a 616 amino acid, full-length
protein (68 kD), while translation from a second ATG
results in a short form (60 kD) that lacks the N-terminal
86 residues of full-length spastin (8). The short form is the
most abundant type in brain and spinal cord and in a variety
of cell lines (8,9). In most tissues and cell lines studied, full-
length spastin is expressed at a low level, although it is
enriched in the adult spinal cord (8,10). All spastin muta-
tions identified in families with autosomal dominant inher-
itance could potentially affect both isoforms, so it is not
clear whether one particular form is important for HSP
pathogenesis.
Spastin is an ATPases associated with diverse cellular
activities (AAA) protein (3). Extensive evidence indicates
that 68 and 60 kD spastin interact with and sever micro-
tubules (MTs) (6,9,11–16). The mechanism of severing has
been clarified recently with the solution of the structure of
the Drosophila spastin AAA ATPase domain. Hexameric
spastin forms a ring with a central pore, into which it is
proposed that the C-terminal tail of tubulin is pulled,
generating a mechanical force that breaks the MT (7).
Consistent with this, endogenous spastin has been re-
ported at regions of active MT regulation, including axonal
branches, the distal axon and the midbody during cell
division (17,18).
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spastin suggested that spastin’s MT-severing activity may
be targeted to organelles on the secretory or endocytic
pathways (19,20). In addition, it is striking that many of the
proteins that interact with spastin have been implicated in
membrane traffic, especially at the early secretory path-
way or at endosomes (Table 1). One of these membrane-
associated binding partners, atlastin, is also an HSP
protein, suggesting that spastin’s role in relation to
membrane traffic may be fundamental to the pathogene-
sis of the disease. Atlastin is located on the secretory
pathway and interacts with a domain within the first 80
amino acids of spastin, so is only able to bind to the 68 kD
form (20).
Spastin’s membrane-associated interactors also include
the endosomal protein CHMP1B, a protein associated with
the endosomal sorting complex required for transport
(ESCRT)-III complex (19). Spastin’s CHMP1B-binding do-
main has been narrowed to a region incorporating its MIT
(MT-interacting and -trafficking) domain (Figure 1), consis-
tent with the observation that MIT domains of several
proteins bind to ESCRT-III members (24). In some cases,
the endosomal location of the MIT domain protein requires
this interaction (24). ESCRT complexes are required for the
formation of, and sorting into, the multivesicular body.
In addition, they have an important role in membrane
modelling events during cell division, where they are
required for the late stage of cytokinesis known as
‘abscission’ or ‘completion’, where the midbody connect-
ing newly divided cells is sealed by addition of new
membrane to generate separated daughter cells (25–27).
During this process, the ESCRT proteins are located on
either side of the densest part of the midbody termed the
Fleming body or stembody, sometimes in a double-ring
structure. The separation of the daughter cells occurs in
association with loss of an abundant parallel array of MTs
within the midbody, although the cellular machinery
responsible for this MT restructuring has not yet been
identified (28,29).
In this paper, we demonstrate that membrane traffic and
MT regulation are coupled through spastin. We show that
endogenous spastin is present on MTs, the early secretory
pathway, endosomes and at the cytokinetic midbody and
that its localization to some of these sites is isoform
specific. ATPase-defective 68 kD spastin delays traffic of
cargo from the endoplasmic reticulum (ER) to the Golgi,
while endogenous spastin is required for completion of
cytokinesis, where it is necessary for a midbody MT
restructuring event that we propose represents spastin-
mediated MT severing.
Table 1: Verified spastin interactors
Verified spastin interactors Subcellular location
Atlastin ER, ERGIC, Golgi (20,21)
CHMP1B Endosomes (19)
NA14 Centrosome (17)
Reticulon1 ER (22)
ZFYVE27 Endosomes (23)
Figure 1: Schematic diagram of
spastin’s domain structure and con-
structs used. Numbering refers to
amino acid position. The regions of
the protein against which the antibod-
ies used in the study (3G11/1 and
spastin86–340) were raised are shown,
as is the position of lysine 388, mutated
to arginine in the K388R constructs.
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Endogenous spastin is located on the early
secretory pathway, endosomes and MTs
Previous work has shown that four spastin isoforms [full
length (68 kD), exon 4-deleted full length (64 kD), short
form (60 kD) and exon 4-deleted short form (55 kD)] are
expressed in mammalian cells (8). Using a sensitive novel
spastin antibody (spastin86–340), we saw bands corre-
sponding to the size of these isoforms in HeLa, MRC5
human lung fibroblast and NSC34 mouse lower motor
neuron neuroblastoma fusion cell lines (Figure S1). In each
cell type, 60 kD spastin was strongly expressed, but 68 kD
spastin expression was much weaker, as previously
reported (8,9).
Using overexpression systems, we have shown that
spastin is present, at least in part, at the ER and endo-
somes (19,20).To testthesefindings with the endogenous
protein, we examined spastin’s subcellular location by
immunofluorescence using a commercial antibody that
worked well for this application (3G11/1; Figure S1).
In general, spastin showed a strong punctate or occasion-
ally filamentous cytoplasmic staining pattern, with signif-
icant nuclear staining in some cells (Figure 2A and Figure
S1). A small proportion of endogenous cytosolic spastin
colocalizedwiththeERinpunctaandtubules(Figure 2A–C).
We saw minimal colocalization of spastin and endogenous
endosomal markers (Figure S2 and data not shown).
However, to reveal any dynamic association between
spastin and endosomes, we used dominant-negative
VPS4. VPS4 normally removes ESCRT complexes and
associated proteins from late endosomes, and the VPS4-
E235Q mutant traps on endosomes proteins, including
ESCRT complex members, that have a transient localiza-
tion there (30). We found strong recruitment of endoge-
nous spastin to endosomes on expression of VPS4-E235Q
in HeLa and NSC34 cells (Figure 2D–F and Figure S2).
As well as these localizations to membrane compart-
ments, we found steady-state colocalization between
spastin and MT markers. This was seen in all cell types
examined but was most clearly observed in MRC5
cells, which have a sparse MT network that facilitates
Figure 2: Endogenous spastin’s sub-
cellular location. A–C) Hela cells labeled
with spastin (A) and calreticulin (B) show
infrequent colocalized puncta (box 1) and
tubules (box 2). D–F) Overexpression of
VPS4-E235Q (E) results in redistribution
of endogenous spastin (D) to VPS4-
E235Q-positive endosomes. G–I) Spastin
(G)tubulin(H)colocalizationwasdetected
in the cytoplasm of MRC5 cells. The
zoomed box shows colocalization on a fil-
ament. J–L) Spastin (J) and tubulin (K)
showed strong colocalization in the mid-
body of cells undergoing cytokinesis. In
(A–C) and (G–I), arrowheads indicate
structures showing co-localisation. In
these and subsequent micrographs, right
hand panels show the merged images;
the colour of each marker in the merged
image is shown by the colour of its letter-
inginthenon-mergedpanels.Scalebarsin
these and subsequent micrographs ¼
10 mm. Formaldehyde fixation.
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there was recruitment of spastin to the midbody where it
colocalized strongly with MTs in formaldehyde-fixed cells
(Figure 2J–L).
In summary, at steady state, spastin colocalized with MTs
in the cell body and midbody and, to a much lesser extent,
with the ER. In addition, a dynamic pool of cytoplasmic
spastin could be strongly recruited to endosomes, from
where its removal requires VPS4.
Spastin’s location at the early secretory pathway
or endosomes is isoform specific
We examined whether recruitment of spastin to the mid-
body, ER or endosomes was isoform specific using
epitope-tagged versions of 60 and 68 kD spastin. Both
spastin isoforms could be recruited to the midbody,
although this recruitment appeared stronger with the
60 kD isoform (Figure S3). At endosomes, there was
strong recruitment of transiently expressed 60 kD myc-
spastin to VPS4-E235Q puncta (Figure 3A–C). This recruit-
ment did not require spastin’s ATPase activity because
a disease-associated mutant version of 60 kD spastin that
is unable to hydrolyze ATP (spastinK388R) was also
recruited to VPS4-E235Q endosomes (data not shown).
However, only a small proportion of the puncta seen on
transient expression of 68 kD myc-spastin colocalized with
VPS4-E235Q (Figure 3D–F). These data indicate that the
60 kD form of spastin is the main endosomal form.
To study the relationship between 60 and 68 kD myc-
spastin and the early secretory pathway, we used vesicular
stomatitis virus G (VSVG)-green fluorescent protein (GFP)
(GFP-tagged temperature-sensitive mutant of the vesicular
stomatitis viral glycoprotein) assays. At a temperature of
408C, this protein is retained in the ER, while on shifting to
a permissive temperature of 328C, it exits the ER in
a synchronized pulse and is transported by the ER-to-Golgi
intermediate compartment (ERGIC) to the Golgi (32). We
found minimal colocalization between 60 kD myc-spastin
Figure 3: Spastin’s recruitment to
membrane compartments is isoform
specific. A–C) Coexpression of 60 kD
myc-spastin (A) and VPS4(E235Q) (B) in
Hela cells shows strong recruitment of
the 60 kD myc-spastin isoform to
VPS4(E235Q) endosomes. D–F) Sixty-
eight kiloDalton myc-spastin (D) and
VPS4(E235Q) (E) coexpressed in Hela
cells show minimal colocalization (arrow-
head). G–I) Hela cells were transfected
with 60 KD myc-spastin (G) and VSVG-
GFP (H). VSVG-GFP has just been
released from the ER in a synchronized
pulse and is concentrated in puncta.
There is no colocalization between
60 kD myc-spastin and VSVG-GFP. J–L)
In contrast, there is strong colocalization
between 68 kD myc-spastin (J) and
VSVG-GFP (K), just after VSVG-GFP
release in a synchronized pulse from the
ER of HeLa cells. Formaldehyde fixation.
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(Figure 3G–I, Figure S4). In contrast, at early time-points
(up to 5 min) after release of VSVG-GFP from the ER, we
found almost complete colocalization between 68 kD myc-
spastin and VSVG-GFP puncta (Figure 3J–L). At later time-
points, this colocalization was lost as the VSVG-GFP
transited to the Golgi. These results indicate that 68 kD
spastin is principally located on the early secretory path-
way (ER and ERGIC), whereas 60 kD spastin is not. The
small amount of endogenous spastin that we saw on the
ER (Figure 2A–C) likely represents 68 kD spastin there.
We next sought to identify functions of spastin at the
membrane sites where we had identified it.
ATPase-defective 68 kD spastin delays
ER-to-Golgi traffic
We first examined the functional role of 68 kD spastin at
the early secretory pathway. Because spastin regulates
MTs, we examined rates of transport of VSVG-GFP bet-
ween the ER and the Golgi apparatus, as this depends on
MT-based vesicular transport (33). We used HeLa cells, as
they express 68 kD spastin (8) and as this assay has been
well characterized in them. To model the effects of a
disease-associated missense mutant, we began by com-
paring the effects of wild-type 68 kD myc-spastin and
ATPase-defective 68 kD myc-spastinK388R on the traffic-
king of VSVG-GFP after its release in a pulse from the ER.
In cells transfected with wild-type 68 kD myc-spastin, just
after release from the restrictive temperature, VSVG-GFP
colocalized strongly with the ER marker calreticulin, as
expected (Figure S5). At 10 min (Figure 4A–D) and 20 min
(Figure 4E–H) after release, VSVG-GFP showed strong and
increasing colocalization with the Golgi marker GM130.
At 60 and 120 min, most of the VSVG-GFP had left the
Golgi and was associated with the plasma membrane (data
not shown and Figure S5). This pattern of VSVG-GFP traffic
was identical to that seen in cells transfected with VSVG-
GFP alone (data not shown).
Expression of 68 kD spastinK388R results in a cellular
phenotype of thickened and bundled MTs that closely
associate with and redistribute the ER (Figure S5) (20). In
contrast to the resultswith wild-type68 kDspastin, incells
expressing this protein, ER-to-Golgi traffic of VSVG-GFP
was considerably delayed. Thus, after 10 min, most VSVG-
GFP remained in the ER, colocalized with the spas-
tinK388R filaments and minimal colocalization with
GM130 was seen (Figure 4I–L). At 20 min, some of the
VSVG-GFP remained in the ER and the majority of it had
not yet reached the Golgi (Figure 4M–P). After 60 min, we
saw strong colocalization between VSVG-GFP and GM130
in most cells (data not shown), and by 120 min, much was
still in the Golgi (Figure S5). Quantification of VSVG-GFP
traffic to the Golgi revealed that, compared with cells
transfected with wild-type 68 kD myc-spastin, VSVG-GFP
had reached the Golgi in a significantly smaller percentage
of 68 kD spastinK388R-transfected cells at 10, 20 or
30 min post VSVG-GFP release (p < 0.002, two-way
ANOVA; Figure 4U).
We examined whether expression of 60 kD myc-spastin or
60 kD myc-spastinK388R affected ER-to-Golgi traffic of
VSVG-GFP and found no delay (Figure S5 and Figure 4U).
Even in 60 kD myc-spastinK388R-transfected cells with
obvious MT bundling, the transport of VSVG-GFP from the
ER to the Golgi did not differ from untransfected cells
(Figure S5), suggesting that 60 kD spastin targets a differ-
ing MT population to 68 kD spastin.
We also examined the effects of depletion of spastin by
small interfering RNA (siRNA). However, we found no
effects on VSVG-GFP trafficking, perhaps because siRNA-
mediated depletion of 68 kD spastin seemed to be rela-
tively inefficient compared with the 60 kD form (Figure
S1), so sufficient 68 kD spastin may have remained.
The ER-to-Golgi traffic defect seen with 68 kD
spastinK388R requires the MTB domain
Because transport of VSVG-GFP from the ER to the Golgi
uses MTs (34), we examined whether the ER-to-Golgi
traffic delay seen with myc-spastinK388R was dependent
on its interaction with MTs. We generated a construct
(termed 68 kD myc-spastinDMTB-K388R; Figure 1) encod-
ing 68 kD myc-spastinK388R but deleted for a MT-binding
(MTB) domain lying between residues 270 and 328 that
has recently been shown in cells and in vitro to be
sufficient for spastin’s MT association and necessary for
MT severing (6). Expression of this protein caused no
obvious MT phenotype (data not shown), although it did
colocalize strongly with the ER marker calreticulin (Figure
S6). VSVG-GFP trafficking in cells expressing this con-
struct was not delayed, with VSVG-GFP showing strong
colocalization with Golgi markers from 10 min after release
from the ER (Figure 4Q–U).
Spastin localizes to midbody double-ring structures
We next turned our attention to 60 kD spastin. Sixty
kiloDalton spastin contains an MIT domain that interacts
with the ESCRT-III protein CHMP1B (19). Because spastin
localizes to endosomes and to the midbody, we examined
whether it had a role in the known functions of the ESCRT
machinery at these sites. We first examined whether
depletion of spastin affected the endosomal degradation
of the epidermal growth factor receptor (EGFR) but found
no significant effect of spastin depletion on EGFR degra-
dation (Figure S7), suggesting that spastin’s function is not
necessary for degradation of this cargo in HeLa cells.
We then examined the role of spastin at the midbody
during cell division, first examining in more detail the
localization of spastin at this site. Following formaldehyde
fixation, spastin appears to be present throughout
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(Figure 2J–L). However, following methanol fixation, while
we still saw some labelling of midbody MTs (data not
shown), spastin signal was concentrated in a double-ring
structure around the stembody. This structure may have
become more prominent after methanol fixation because it
was revealed by removal of soluble spastin or because
methanol fixation is more favourable to capturing short-
lived interactions or revealing epitopes hidden in complex
structures. The spastin double-ring structure partially co-
localized with the midbody markers Aurora B and PRC1
(Figure 5A–F) (35,36). This double-ring localization was
strikingly reminiscent of the appearance described for
VPS4 and some ESCRT proteins in the midbody (26,27),
and indeed, the spastin double-ring structures showed
strong colocalization with VPS4-E235Q (Figure 5G–I), sug-
gesting that they represent spastin in association with
ESCRT proteins.
The MIT domain is required for spastin’s
recruitment to the midbody
The midbody protein CEP55 recruits the ESCRT-1 protein
TSG101 and the ESCRT-associated protein Alix to the
midbody. Alix in turn recruits ESCRT-III proteins to the
midbody, and this recruitment is essential for normal
abscission (26,27). Mammalian spastin’s MIT domain is
not necessary for its interaction with MTs (6) but does
interact with the ESCRT-III protein CHMP1B (19). We
therefore investigated whether this domain is required
for recruitment of spastin to the midbody. We expressed
a form of spastin deleted for the N-terminal region and
MIT domain (myc-spastinDN194; Figure 1) and found
no recruitment of this construct to the midbody (Figure
6A–C). In addition, we found no recruitment of myc-
spastinDN194 to VPS4-E235Q endosomes in the cell body
(Figure 6A–C).
We then examined whether spastin’s ability to bind to MTs
affected its localization at the midbody. We generated
a construct (60 kD myc-spastinDMTB; Figure 1) encoding
residues 87–616 of spastin but deleted for the MTB
domain. Under conditions of formaldehyde fixation, dele-
tion of the MTB domain did not prevent recruitment of
spastin to the midbody but, compared with wild-type
60 kD myc-spastin (Figure S3), did alter the pattern of its
distribution within the midbody. Instead of colocalizing
with MTs throughout the intercellular bridge, it was found
in a double-ring structure on either side of the stembody
that showed only partial colocalization with MTs (Figure
6D–F). These structures were very similar to those found
with endogenous spastin after methanol fixation, suggest-
ing that methanol fixation reveals a pool of midbody
endogenous spastin that is not associated with MTs.
We conclude from these experiments that spastin’s
recruitment to the midbody requires the MIT domain but
not the MTB domain.
Spastin is required for abscission
We next investigated whether depletion of spastin caused
abnormalities in cytokinesis. In HeLa and MRC5 cells,
spastin depletion using an siRNA pool caused a proportion
of cells to be connected by extended tubular structures
that labeled strongly with antibodies to acetylated, tyrosi-
nated or total tubulin (Figure 7A–C). These structures were
long and often convoluted and were sometimes accom-
panied by puncta that labeled strongly with MT markers
(Figure 7B). We also saw them when spastin was
depleted using four independent siRNA oligonucleotides,
strongly suggesting that they were not the result of an off-
target effect (Figure 7D–F and data not shown). Typically,
the tubules connected two cells (Figure 7G–I), and some-
times, they resembled elongated midbodies. In these
cases, they labeled with midbody markers, indicating that
they were elongated versions of the intercellular bridges
that form between daughter cells following nuclear divi-
sion (Figure 7J–L). We saw similar intercellular tubules in
a proportion of cells expressing ATPase-defective 60 kD
myc-spastinK388R (Figure 7M–O) but not 68 kD myc-
spastinK388R.
These results strongly suggested that spastin is required
for completion of a late stagein cytokinesis. We used time-
lapse microscopy of HeLa cells stably expressing yellow
Figure 4: Sixty-eight kiloDalton spastinK388R delays ER–Golgi traffic of VSVG-GFP. Hela cells were cotransfected with VSVG-GFP
and 68 kD myc-spastin (A–H), 68 kD myc-spastin K388R (I–P) or 68 kD myc-spastinDMTB-K388R (Q–T). VSVG-GFP was then released in
a pulse from the ER. A–H) In cells expressing 68 kD myc-spastin (A and E), VSVG-GFP fluorescence (B and F) had left the ER and was
strongly associated with the Golgi marker GM130 (C and G) at 10 min (A–D, arrow) and 20 min (E–H) post release. I–L) In contrast, at
10 min post release in cells expressing 68 KD myc-spastin K388R (I), VSVG-GFP (J) remained predominantly in the ER on myc-
spastinK388R-positive MT bundles (arrowheads) and only a few VSVG-GFP-positive vesicles had left the ER. In most cells, VSVG-GFP
showed minimal or no colocalization with the Golgi (K). M–P) At 20 min, although some VSVG-GFP (N) was retained on the myc-
spastinK388R-positive MT bundles (arrowheads), most had emerged. However, much of the VSVG had not reached the Golgi (O), as
demonstrated by the presence of green vesicles in the merged image (P). The Golgi often appeared fragmented in cells expressing 68 kD
myc-spastinK388R (K and O). Q–T) Ten minutes after VSVG-GFP release in cells expressing 68 kD myc-spastinDMTB-K388R (Q), VSVG-
GFP (R) showed strong colocalization with the Golgi (S). U) Quantification of these results showed that, at each time, VSVG-GFP had
reached the Golgi in a smaller percentage of cells transfected with 68 kD myc-spastinK388R (n ¼ 3 experiments), compared with other
spastin constructs tested (p < 0.002, two-way ANOVA; n ¼ 3 for each spastin construct). The total number of cells counted at each time is
indicated above the relevant bar. Error bars ¼ SEM. Formaldehyde fixation.
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cells, the midbody MTs that extend from each daughter
cell into the intercellular bridge abruptly break down
approximately 2 h after anaphase onset (Figure 8A and
Video S1) in an event that precedes the final abscission
event. In some cells, we saw constriction of the intercel-
lular bridge immediately preceding the loss of midbody
MTs (Video S1), consistent with previous reports (28,37).
In contrast, in spastin-depleted cells, this MT disruption
event was severely delayed or did not occur (Figure 8B,C
and Video S1). Instead, the intercellular bridge became
progressively thinner and fainter but persisted for many
Figure 6: The MIT domain but not
the MTB domain is required for
recruitment of spastin to the mid-
body. A–C) Myc-spastinDN194 (A) was
not recruited to VPS4(E235Q) struc-
tures (B) in the cell body or midbody
(box). D–F) 60 kD myc-spastinDMTB
(D) is expressed in a double-ring struc-
ture on either side of the stembody, but
unlike wild-type 60 kD myc-spastin
(Figure S3), does not colocalize with
alpha-tubulin (E) throughout the inter-
cellular bridge. Formaldehyde fixation.
Figure 5: Spastin localizes to
double-ring structures in the
midbody of methanol-fixed cells.
A–F) In HeLa cells fixed with meth-
anol, endogenous spastin (A and D)
colocalizes with the midbody
markers Aurora B (B) and PRC1
(E). Note the double-ring appear-
ance of spastin on either side of
the stembody, most obvious in (A).
G–I) Spastin (G) also colocalizes
with GFP-VPS4A(E235Q) (H) in dou-
ble-ring structures in the midbody,
in methanol-fixed HeLa cells.
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structures that we had seen by immunofluorescence
(Figure 7A). We saw these effects both when spastin
was depleted using a pool of siRNA oligonucleotides
(Figure 8B,C and Video S1) and when each oligonucleotide
was used independently (Figure S8). Although abscission
clearly failed in these cells, we did not see re-fusion of
daughter cells, and we only saw a slight increase in
multinucleate cellsinfixedpreparations [ratio ofnuclei/cells:
mock ¼ 1.02 (n ¼ 224 cells), spastin knock down ¼ 1.05
(n ¼ 213 cells)]. Therefore, this failure in abscission is
distinct from that occurs when MTs are not properly
organized in the midbody, for example following depletion
of the MT-bundling protein PRC1 (38), and it seems likely
that spastin is not required for midbody organization or
function until late in cytokinesis. Spastin plays a role in
mitosis in Drosophila, where it contributes to the rapid
MT dynamics of the mitotic spindle (39). However, we
were unable to measure any convincing effect of spastin
depletion on the timing of mitosis up to anaphase
(Figure 8D and Figure S8), arguing that if spastin plays
a similar role in human cells, either this is not essential
for mitotic spindle dynamics or the small amounts of
spastin left after depletion are sufficient to carry out this
function.
We concluded that spastin plays an essential role in
causing a MT disruption event that is necessary for
completion of the abscission stage of cytokinesis of
human cells.
Figure 7: Spastin depletion causes
the appearance of MT-filled intercel-
lular bridges. A–C) Hela (A and B) and
MRC5 (C) cells were labeled with alpha-
tubulin following spastin depletion with
pooled siRNA oligonucleotides 1–4.
Note long intercellular bridges (arrow-
heads) that were sometimes very con-
voluted (B). Alpha-tubulin-labeled
puncta were often seen in association
with these bridges (arrow in B). D and
E) The intercellular bridges (arrow-
heads) were also seen following spas-
tin depletion using two individual
spastin siRNA oligonucleotides. Suc-
cessful spastin depletion in these ex-
periments is verified in (F). G–I) The
intercellular bridges (arrowheads) typi-
cally joined two cells, as shown in DIC
image (G) of YFP–tubulin (H)-express-
ing HeLa cells depleted of spastin. J–L)
Some of the intercellular bridges had
the appearance of very elongated
midbodies, which labeled with midbody
markers [e.g. aurora B; (K)] as well as
with MT markers (J). M–O) Hela cells
transfected with 60 kD myc-spas-
tinK388R (M) and labeled for alpha-
tubulin (N) also displayed similar
intercellular bridges (arrowhead). Form-
aldehyde was used in fixed prepara-
tions except (J–L) where methanol
was used.
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Spastin is a MT-severing enzyme that has a key role in the
pathogenesis of HSP. Not only are mutations in the spastin
gene the most frequent cause of HSP but it also directly
interacts with another HSP protein, atlastin (20,21). Eluci-
dating its function is therefore crucial to understand HSP
pathogenesis. Its study is also of general cell biological
importance because it may reveal mechanistic insights
into cellular processes in which MT severing plays a role.
This study provides the first direct evidence that endoge-
nous spastin can be recruited to membrane traffic path-
ways. Taken together with our previous studies (19,20),
our results show that endogenous spastin is located at
endosomes and at the early secretory pathway and that
recruitment to these sites is isoform specific. In the
present study, we found that 60 kD spastin was recruited
to endosomes but not the secretory pathway, while 68 kD
spastin is mainly located in the ER and very early ER-to-
Golgi transport compartments. Our findings therefore
suggest that spastin is a MT-severing enzyme that is
recruited to different sites on membrane traffic pathways.
What factors might be responsible for recruiting spastin to
its different sites of action? While spastin’s C-terminal half
contains the AAA domain crucial for MT severing, its
N-terminal half mediates interactions with at least five
Figure 8: Spastin is required for completion of cytokinesis. A)Time -lapse seriesofcontrol glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) siRNA-treated cells, showing the disruption of MTs in the intercellular bridge, on either side of the stembody (arrowheads) at
approximately 2 h after anaphase. Times after anaphase shown in min. B) Time-lapse series of YFP–tubulin cells depleted of spastin. The MT
disruption eventdoes notoccur. Cellsremain attached by a microtubule-rich intercellular bridge(arrow).C)Cumulative timing of MT disruption
event shown in (A). In control cells, the time from anaphase to MT disruption was measured. In spastin-depleted cells, where this event is
delayed or does not occur, it was often not possible to measure (e.g. when it was after the end of filming). We plotted minimum timings for
these cells, underestimating the effect of spastin depletion. Control cells, n ¼ 57; spastin-depleted cells, n ¼ 64, obtained from four
independent experiments. p < 0.0001 (Student’s t-test). D) Cumulative timing of anaphase onset in YFP–tubulin cells. Time from nuclear
envelope breakdown (NEBD) to separation of duplicated chromosomes at anaphase was measured. Control cells, n ¼ 21 (obtained from four
experiments); spastin-depleted cells, n ¼ 41 (obtained from three experiments). Error bars ¼ SDs.
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secretory pathway clearly depends on the N-terminal 86
residues of 68 kD spastin, which the 60 kD form lacks.
This localization may be mediated by spastin’s interaction
with the ER protein reticulon1 (22). The HSP protein
atlastin is present on the early secretory pathway and is
able to bind to 68 kD, but not 60 kD, spastin (20,40). In
neuronal cells, where it is highly expressed, atlastin
binding could be an additional determinant of 68 kD
spastin’s recruitment to the secretory pathway. Spastin
also contains an MIT domain that binds to the ESCRT-III
protein CHMP1B (19). Deletion of spastin’s MIT domain
prevented its recruitment to endosomes, suggesting that
its localization to this site is mediated by MIT–ESCRT-III
interactions. Thus, spastin’s localization may be influenced
by interactions with a variety of adaptor proteins.
With the caveat that our results relied on an overexpres-
sion system, we found that 68 kD spastin functions in ER-
to-Golgi traffic because expression of ATPase-defective
68 kD spastinK388R significantly delayed ER-to-Golgi traf-
fic of VSVG-GFP. This effect depended on its ability to
interact with MTs by the MTB domain. Budding from ER
exit sites and transport from ER-to-Golgi is dependent on
MT dynamics and motility, so we speculate that disruption
of ER-associated MTs caused by spastin mutation affects
one or both of these processes (34,41). The notion that
68 kD spastin is involved in formation and transport of ER-
to-Golgi carriers fits well with reports that expression of
atlastin mutants disrupts vesicular budding from the ER
and traffic of ER-to-Golgi transport intermediates (42).
Although a recent publication has suggested that expres-
sion of atlastin mutants does not affect VSVG-GFP traffic
(43), this publication did not report on early time-points
after VSVG-GFP release from the ER when we found the
most significant effects of spastin mutation.
The observation that 60 kD spastin can localize to endo-
somes adds it to the group of HSP proteins that localize to
thissite,which includes NIPA1,maspardin andspartin(44–
46).Althoughwedidnotfindeffectsofspastindepletionon
endosomal EGFR degradation, we identified a role for
mammalian spastin in another process that requires the
ESCRT machinery, cytokinesis. During cytokinesis in ani-
mal cells, contraction of an equatorial actomyosin ring
drives cleavage of the cell and compaction of bundled,
antiparallel MTs into a structure termed the midbody (47).
The MTs are embedded in the densest part of the midbody
known as the stembody or Fleming body. The daughter
cells remain connected by a thin, MT-packed bridge of
plasma membrane-bound cytoplasm for some time after
cleavage. The midbody is essential for the formation and
maintenanceofthisintercellularbridgeaswellasforitsfinal
resolution (47). Consistent with previous reports, we found
that endogenous spastin localizes to the midbody (17).
Early description of the completion of cytokinesis
described constriction of the intercellular bridge that
occurs before the final separation of daughter cells (37).
More recently, imaging of MTs in live cells has shown that
this corresponds to loss of MTs in the intercellular bridge,
although the machinery required has not been identified
(28,29). In this study, we have shown that, in human cells,
the disruption of MTs that accompanies abscission re-
quires spastin. Although gradual thinning of the intercellu-
lar bridge occurred in cells lacking spastin, the MT
disruption event in the half-bridges on either side of the
stembody that normally accompanies abscission did not
occur. Instead, midbody breakage failed, and daughter
cells remained attached by thin, frequently very extended
intercellular bridges for many hours. These results strongly
suggest that spastin is part of the machinery of abscission,
and we speculate that the MT disruption event, which
appears to be essential for this process, represents
spastin-mediated severing.
The final step in abscission also requires resolution of the
plasma membrane between the daughter cells, and mem-
brane traffic machinery is necessary for this (29,48,49). Of
particular interest in the context of spastin’s interaction
with the ESCRT-III complex-associatedprotein CHMP1B is
the role of ESCRT-I and ESCRT-III proteins and the ESCRT-
associated protein ALIX. Depletion of ALIX, abrogation of
its interaction with the ESCRT-III protein CHMP4 or
expression of dominant-negative VPS4-K173Q, which
traps ESCRT proteins on endosomes and disrupts their
function, all result in a failure of abscission accompanied by
subsequent re-fusion of daughter cells and a consequent
high incidence of multinucleation (26,27). Although final
cleavage of the midbody plasma membrane failed in
spastin-depleted cells, the effect of spastin depletion
was different to that seen with manipulations of the
ESCRT machinery because there was no significant
increase in multinucleated cells in fixed preparations, and
no re-fusion of daughter cells, even after extended periods
of time-lapse microscopy. It is possible that the point at
which spastin is required in abscission is late and beyond
the time at which daughter cells are capable of re-fusing,
although we cannot exclude the possibility that spastin
may play an additional role in re-fusion of daughter cells
after failure to resolve the plasma membrane. Neverthe-
less, we conclude that spastin is required for resolution of
the midbody plasma membrane.
The ESCRT and VPS4 proteins involved in cytokinesis
localize to a double-ring structure on either side of the
stembody (27). Formaldehyde fixation revealed endoge-
nous spastin throughout both sides of the midbody, where
it colocalized with MTs. However, after methanol fixation,
double-ring structures surrounding the stembody, and
strikingly similar to those seen with some ESCRT proteins,
were more prominent. These double-ring structures
showed only limited colocalization with MTs, and similar
structures were seen on expression of MTB domain-
deleted spastin. When considered with the strong coloc-
alization that we saw in the midbody between endogenous
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that the double-ring spastin labelling represents a non-MT-
associated pool that is interacting with ESCRT complex
members. The ESCRT-III-interacting MIT domain was
required for spastin to be located in the midbody. We
therefore suggest that spastin is positioned in the midbody
by the ESCRT-related cytokinetic machinery, where it then
interacts with MTs and carries out a MT-severing function
crucial for the completion of abscission. The MTB domain
is likely to be essential for this function because although it
is not required for spastin to localize in the midbody, it is
necessary for MT severing (6) and for spastin to colocalize
with midbody MTs.
What is the relevance of our findings to spastin’s role in the
axon? Recent work indicates that spastin is involved in
promoting axonal branching (18). Axonal branching requires
delivery of new membrane to the branch site, and early
studies showed that MT disruption in the area of the new
branch point is necessary and sufficient to promote delivery
of membrane-bound cargoes that can insert membrane into
the growing branch (50). It has been suggested that new
membrane required for axonal branching is derived from
a specialized endosomal compartment (51). Because
expression of spastin in axons results in decreased MT
mass and formation of abundant short MTs, it is likely that
the increased branching seen on expression of spastin is as
a result of its MT-severing activity (18). Thus, axonal
branching resembles the other situations in which we have
found spastin because it requires closely co-ordinated
membrane traffic and MT regulation. Further work will be
required toidentifythe precise relationship between spastin
and membrane traffic compartments in axons. However,
based on analogy with spastin’s recruitment to endosomes
and to the midbody, we speculate that spastin may be
concentrated at axonal branch points and the growth cone
following recruitment by membrane-associated adaptors,
perhaps including atlastin and ESCRT-III proteins.
Although a model for spastin’s role in developing axons is
emerging, it is not yet clear how this might relate to the
axonal degeneration seen in HSP, which cannot involve
defects of axonal branching or growth. However, the
relationship that we have identified between spastin and
membrane traffic processes, against the background of
numerous other HSP gene products being involved in
endocytosis or secretion, points to the likelihood that this
will involve failure of membrane traffic-related functions.
Materials and Methods
Constructs
A schematic diagram of the constructs used is shown in Figure 1.
Synthesis of pcDNA3.1(þ) mammalian expression plasmids containing
68 kD wild-type, 68 kD myc-spastinK388R and myc-spastinDN194 has
been described previously (19,20). Sixty kiloDalton (deleted for the
N-terminal 86 amino acids) myc-spastin and myc-spastinK388R were made
from the full-length constructs using Phusion Site-Directed Mutagenesis
(Finnzymes), according to the manufacturer’s instructions. MT-binding-
domain-deleted (DMTB, lacking amino acids 270–328) versions of 60 and
68 kD myc-spastin were made in the same way. Constructs were
sequence verified before use. The temperature-sensitive ts045 VSVG-
GFP construct was a kind gift from Rainer Duden (University of London),
and the GFP-VPS4E235Q construct was a kind gift from Paul Whitley
(University of Bath).
Antibodies
Rabbit polyclonal anti-spastin86–340, used for immunoblotting of spastin,
was raised (Harlan SeraLabs) against a glutathione S-transferase fusion
protein that we synthesized incorporating residues 86–340 of spastin.
Mouse anti-spastin monoclonal antibody (3G11/1), used for immunoblotting
and immunofluorescence, was obtained from Santa Cruz Biotechnology.
Mouse monoclonal anti-myc antibody (clone 4A6) was obtained from
Upstate. Rabbit polyclonal anti-GFP (6556), rabbit polyclonal anti-aurora B
and rat polyclonal anti-tyrosinated tubulin (YL1/2) were obtained from
Abcam. Rabbit polyclonal anti-myc antibody (A14) and rabbit anti-EGFR
(1005) antibody were obtained from Santa Cruz Biotechnology. Rabbit
polyclonal anti-calreticulin antibody was obtained from Calbiochem. Mouse
monoclonal anti-GM130 antibody was obtained from BD Transduction
laboratories. Mouse monoclonal alpha-tubulin (clone DM1A), acetylated
tubulin (clone 6-11B-1) and rabbit polyclonal anti-actin antibodies were
obtained from Sigma. Rabbit polyclonal anti-PRC1 was a kind gift of Tony
Hunter (San Diego). Rabbit polyclonal mannose 6 phosphate antibody was
produced as previously described (52). Peroxidase-conjugated secondary
antibodies for western blotting were obtained from Sigma. Alexafluor-488-,
Alexafluor-568- and Alexafluor-647-labeled secondary antibodies for immu-
nofluorescence were obtained from Molecular Probes.
Cell culture
HelaM cells were maintainedinDMEMcontaining10%(v/v)FBS, 100 U/mL
penicillin, 100 mg/mL streptomycin and 2 mML -Glutamine (Sigma). HeLa
cells stably expressing YFP-tagged tubulin for time-lapse analysis were
additionally cultured in the presence of 500 mg/mL Geneticin (Invitrogen).
For time-lapse microscopy, cells were seeded onto glass bottom dishes
(WillCo Wells BV). DMEM was replaced with Leibovitz’s L-15 medium
(Invitrogen) before filming.
Transfection and immunofluorescence
For siRNA transfections, a double-hit knock down protocol was used, as
previously described (53). Briefly, 1   10
5 HeLaM cells (54) were plated in
a well of a six-well plates and subsequently transfected on two occasions,
48 h apart, using Oligofectamine transfection reagent (Invitrogen), accord-
ing to the manufacturer’s instructions. For DNA transfections, HeLaM cells
were plated onto poly-L-lysine (Sigma)-coated coverslips and transfected
24 h later using Effectine
 transfection reagent (Qiagen). Twenty-four
hours post transfection coverslips were directly processed for immuno-
fluorescence microscopy or first used for ts045 VSVG-GFP transport
assays. For immunofluorescence, typically, cells were fixed at room
temperature in 4% (v/v) formaldehyde in PBS and permeabilized in PBS
containing 0.1% (v/v) Triton-X-100 (Sigma). For certain markers (Aurora B
and PRC1), cells were fixed and permeabilized in methanol. Coverslips
were incubated in blocking buffer containing 10% (v/v) FBS in PBS for
30 min before incubation with specific monoclonal or polyclonal antibodies
for 1 h. Coverslips were washed several times in blocking buffer before
incubation with secondary antibody for 1 h. Following this final incubation,
coverslips were washed several times in blocking buffer, followed by
subsequent washes with PBS and distilled water before being mounted on
glass slides with anti-fade Gold mounting medium (Invitrogen). Slides
were analysed at room temperature with a Zeiss 510 Meta confocal
microscope ( 63 oil immersion objective) with LSM Image analysis
software. Images were subsequently processed using ADOBE PHOTOSHOP
and ILLUSTRATOR.
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siRNA oligonucleotides to spastin were obtained from Dharmacon Inc.
(Perbio Science UK). Human spastin individual siGENOME duplexes (SPG4)
(D-014070-01 – 04; siRNA1 50- UUAUAGAAGGUUGAAGUUCUU; siRNA2
50- UCAUUAUAGACGUCCGUUUUU; siRNA3; 50- UAAACUUGCAGCA-
CUUAUAUU; siRNA4 50- UUAGCCAGCAUUGUCUUCCUU; Dharmacon)
were optimized for gene-silencing efficiency and used between 5 and
20 nM singly or in a 5 nM (total concentration) pool.
Time-lapse microscopy
Time-lapse recordings of HeLa YFP–tubulin cells were made using a Delta-
Vision Spectris microscope (Applied Biosystems) fitted with 378C chamber.
YFP –tubulin images were collected with a  60 1.4 numerical aperture
objective, as a series of 12   1 mM Z-stacks at 5 or 10 min intervals,
together with a single differential interference contrast microscopy (DIC)
reference image. Fluorescence was viewed as projections of maximum
pixel intensities of each stack onto a single plane and exported in 16-bit TIFF
format using IMAGEJ (National Institutes of Health). DIC images were used
to determine the time of nuclear envelope break down and of the onset of
anaphase.
EGFR degradation assay
Mock -transfected HeLaM cells or HeLaM transfected with spastin siRNA
were serum starved overnight and then treated with 100 ng/mL of EGF
(Calbiochem) in the presence of cycloheximide (10 mg/mL). At selected
time-points, cells were washed with cold PBS and then harvested into 1 
Laemmli sample buffer. Samples were run on SDS–PAGE and immuno-
blotted to detect EGFR. EGFR band density was quantified using a Geldoc
GS-710 densitometer and QUANTITY ONE software (Bio-Rad). Density values
were normalized versus those of the corresponding unstimulated sample,
and the results were analysed in GRAPHPAD PRISM 5.01 for Windows
(GraphPad Software).
ts 045-VSVG-GFP assays
HelaM cells were cotransfected with 60 or 68 kD wild-type or ATPase-
defective K388R myc-spastin constructs and ts045 VSVG-GFP. Twenty-
four hours post transfection cells were incubated at 408C for 16 h. For
0 min time-point, cells were fixed at 408C, and for all subsequent time-
points, cells were incubated in media preconditioned to 328C and fixed at
the same temperature. Following the temperature shift, cells were
processed for immunofluorescence as previously described or used for
endo H digestion assays. Coverslips were manually scanned for cotrans-
fected cells, and individual cells were counted. Histograms and statistical
analyses were made using GRAPHPAD PRISM.
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Supporting Information
Additional Supporting Information may be found in the online version of
this article:
Figure S1: Verification of spastin antibodies and spastin expression
pattern. Two spastin antibodies were used in this study, spastin 3G11/1
and spastin86-340. Both were raised against epitopes present in the 60 and
68 kD spastin isoforms (Figure 1). A) Immunoblot of mock-transfected Hela
cells or HeLa cells transfected with pooled spastin siRNA oligonucleotides
1–4, blotted using spastin86–340 antibody. Sixty-eight, 64, 60 and 55 kD
bands are visible in the mock-transfected sample, while the 60 and 55 kD
bands are lost following siRNA-mediated spastin depletion. Similar effects
were found when the siRNA oligonucleotides were used individually. Actin
blotting is shown to verify equal loading. B) Immunoblot of mock-trans-
fected Hela cells or HeLa cells transfected with spastin siRNA, blotted
using spastin 3G11/1 antibody. For immunoblotting, 3G11/1 was less
sensitive than the spastin86-340 antibody, but it was able to detect the
strong 60 kD band. Actin blotting verifies equal loading. C) Immunoblots
using spastin86–340 in the cell lines indicated. D and E) In HeLa cells
transfected with pooled spastin siRNA oligonucleotides 1–4 (E) and labeled
with anti-spastin 3G11/1, spastin labeling is lost compared with mock-
transfected HeLa cells (D). Images taken with identical confocal micro-
scope settings. Asterisks in (D) indicate cells showing nuclear spastin
labeling. Spastin86–340 did not specifically detect endogenous spastin
under immunofluorescence. F) Hela cells labeled with anti-spastin 3G11/1
occasionally showed filamentous structures, labeled by arrowheads in the
inset box. Scale bars in these and all subsequent micrographs ¼ 10 mm.
In these and all subsequent supplementary figures, images were obtained
from cells fixed with formaldehyde.
Figure S2: Endogenous spastin labeled with selected markers. A–C)
Hela cells labeled with antibodies to spastin (A) and mannose 6 phosphate
receptor (M6PR), a marker of late endosomes (B). There is minimal
colocalization (C). D–F) Endogenous spastin (D) was recruited to
VPS4E235Q-positive endosomes (E) in transiently transfected NSC34 cells.
Figure S3: Localization of spastin isoforms at midbody. A–C) Hela cells
transfected with 60 kD myc-spastin (A) show colocalization with alpha-
tubulin (B) in the midbody. D–F) Sixty-eight kiloDalton myc-spastin (D)
shows partial colocalization with alpha-tubulin (E) in the midbody of HeLa
cells.
Figure S4: Sixty kiloDalton spastin is not localized to the early
secretory pathway. Hela cells were transfected with 60 kD myc-spastin
(A–C) or 60 kD myc-spastinK388R (D–F). There was no colocalization
between 60 kD myc-spastin (A) or 60 kD myc-spastinK388R (D) and
calreticulin (B and E). Note also that although 60 kD myc-spastinK388R
does bundle MTs, it does not cause redistribution of the ER, unlike 68 kD
myc-spastinK388R.
Figure S5: ATPase-defective 68 kD spastin but not 60 kD spastin
delays ER–Golgi traffic. HeLa cells were cotransfected with VSVG-GFP
and 68 kD myc-spastin (A–H), 68 kD myc-spastinK388R (I–P), 60 kD myc-
spastin (Q–T) or 60 kD myc-spastinK388R (U–X). VSVG-GFP was then
released in a pulse from the ER, and cells were examined at the time-points
indicated. A–D) In cells expressing 68 KD myc-spastin (A), just after VSVG-
GFP release, some VSVG-GFP puncta (B) are beginning to emerge from the
ER (C) and these colocalize with 68 kD myc-spastin (arrowheads). E–H) At
120 min after release, VSVG-GFP (F) is strongly associated with the plasma
membrane (note membrane ruffles in F). Sixty-eight kiloDalton myc-spastin
expression (E) remained unchanged from earlier time-points, appearing as
cytosolic puncta. I–L) In Hela cells transfected with 68 kD myc-spas-
tinK388R (K), there was a complete redistribution of the ER (I) onto tubular
structures that also contain bundled MTs (data not shown). Just after
shifting to the permissive temperature, these tubules label strongly with
VSVG-GFP (J). M–P) At 120 min following the temperature shift, the
colocalization between 68 kD myc-spastinK388R (M) and VSVG-GFP (N)
seen at earlier time-points is lost and there is partial colocalization between
VSVG-GFP and GM130 (O) (inset). Plasma membrane fluorescence is
minimal.Q–T)Incellsexpressing60 kDmyc-spastin(Q),10 minafterrelease
from the ER, VSVG-GFP (R) strongly colocalized with the Golgi marker
GM130 (S; arrowheads). U–X) Expression of 60 kD myc-spastinK388R
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expressing cells (U), with diffuse and punctate cytoplasmic staining in lower
expressing cells (data notshown).At 10 minafter release from theER, VSVG-
GFP (V) was strongly colocalized with the Golgi marker GM130 (W; inset).
Figure S6: Sixty-eight kiloDalton myc-spastinDMTB-K388R colocal-
izes with the ER. A–C) Transiently expressed 68 kD myc-spastinDMTB-
K388R (A) colocalized with the ER marker calreticulin (B) in HeLa cells.
Figure S7: Depletion of spastin has no effect on EGFR degradation. A)
ArepresentativeEGFRdegradationassay.Mock-transfectedHeLacellsorHeLa
cells transfected with spastin siRNA were serum starved overnight and then
stimulatedwith100 ng/mLofEGFinthepresenceofcycloheximide.Cellswere
harvestedat theindicatedtime-pointsand immunoblottedversusspastin,using
spastin86-340antibody,orEGFR.Actinblottingisshowntoverifyequalloading.
B) EGFR immunoblots were quantified by densitometry in six independent
experimentscarriedoutasin(G).Errorbarsrepresent95%confidenceintervals.
Figure S8: Spastin depletion by four individual siRNA oligonucleo-
tides delays completion of cytokinesis. A) Representative experiments
showing cumulative timings of the cytokinesis-associated MT disruption
event in mock-transfected YFP–tubulin HeLa cells or YFP–tubulin cells
transfected with individual spastin siRNA oligonucleotides 1, 2, 3 or 4.
Timings were obtained as described in Figure 8. Spastin depletion with
each oligonucleotide caused a delay in the midbody MT disruption event
after anaphase. A representative immunoblot showing the effect of the
individualsiRNAsonendogenousspastinisshown.The60 kDspastinisoform
iseffectivelydepletedbyallfouroligonucleotides.However,oligonucleotide2
(whose target sequence is in spastin exon 4) does not deplete the 55 kD
spastin isoform (asterisks), and interestingly, this oligonucleotide had the
smallest effect in delaying the MT disruption event. p   0.0001 for timings
aftertreatmentwitheacholigocomparedwithtimingsfrommock-transfected
cells (Student’s t-test). Number of cells analysed: mock ¼ 43, siRNA1 ¼ 12,
siRNA2 ¼ 45, siRNA3 ¼ 44 and siRNA4 ¼ 11. B) Representative experi-
ments showing cumulative timing of anaphase onset in mock-transfected
YFP–tubulinHeLacellsorYFP–tubulincellstransfectedwithindividualspastin
siRNA oligonucleotides 1, 2, 3 or 4. Time from nuclear envelope breakdown
(NEBD) to separation of duplicated chromosomes at anaphase was mea-
sured. Number of cells analysed: mock ¼ 39, siRNA1 ¼ 6, siRNA2 ¼ 36,
siRNA3 ¼ 52 and siRNA4 ¼ 10. C) Time-lapse series of mock-transfected
HeLa YFP–tubulin cells to illustrate how timings of NEBD and anaphase were
determined. Both DIC imaging and the distribution of YFP–tubulin fluores-
cence reveal NEBD between the 5 and the 10 min time-points in this series.
Anaphase ismeasured asthe point of separation ofduplicatedchromosomes
seen by DIC, or the elongation of the mitotic spindle seen by YFP–tubulin
fluorescence, seen here at the 30 min time-point.
Video S1: Movie of HeLa cells stably transfected with YFP–tubulin
undergoing cytokinesis. The cell on the left is a control cell, whereas the
cell on the right is from a population depleted of spastin by siRNA. These
cells correspond to time-lapse images shown in Figure 8.
Please note: Wiley-Blackwell are not responsible for the content or
functionality of any supporting materials supplied by the authors. Any
queries (other than missing material) should be directed to the correspond-
ing author for the article.
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